-
摘要:
目的 探讨GDP方案和CHOP方案治疗非特异性外周T细胞淋巴瘤（PTCL-U）的疗效和安全性。 方法 回顾性分析自2008年1月至2011年12月郑州大学第一附属医院淋巴瘤诊疗中心收治经病理学确诊的PTCL-U患者29例。14例患者应用GDP方案，15例应用CHOP方案。采用χ2检验和Log-Rank检验，对两组的疗效及不良反应进行分析和比较。 结果 接受GDP方案化疗的非特异性外周T细胞淋巴瘤患者总有效率（RR）为78.57%，而CHOP组为60.00%，两组比较差异有统计学意义（P < 0.05）。GDP组无进展生存期（PFS）为9.79个月，总生存期（OS）为17.36个月；CHOP组PFS为4.2个月，OS为11.27个月，两组比较差异均有统计学意义（P < 0.05）。主要不良反应为血液学毒性，其中GDP方案Ⅲ~Ⅳ度血液学毒性发生率57.14%，CHOP方案Ⅲ~Ⅳ度血液学毒性为33.33%。 结论 GDP方案治疗外周T细胞淋巴瘤疗效优于传统CHOP方案，虽然血液学毒性稍重，仍值得临床推广，并有望成为PTCL治疗的一线方案。 -
关键词:
- 非特异性外周T细胞淋巴瘤 /
- GDP方案 /
- 疗效 /
- 安全性
Abstract:Objective This study aims to investigate the efficacy and safety of GDP chemotherapy for nonspecific peripheral T-cell lymphoma (PTCL) compared with the CHOP regimen. Methods Between January 2008 and December 2011, 14 nonspecific PTCL patients were treated with the GDP regimen and 15 were treated with the CHOP regimen. The curative effects and the adverse reactions were analyzed and compared between the two groups by χ2 text and Log-Rank test. Results The overall response (OR) rate was 78.57 % among the patients in the GDP group and 60 % in Objectives: the CHOP group. Statistically significant differences were observed between the two groups (P < 0. 05). The progression-free survival (PFS) rate was 9.79 months in the GDP group and 4.2 months in the CHOP group. The overall survival (OS) was 17.36 months in the GDP group and 17.27 months in the CHOP group. Statistically significant differences were observed between the two groups (P < 0. 05). The main side effect was bone marrow depression, and grade 3 or grade 4 hematologic toxicity occurred in 18.42% of the patients in the GDP group and 33.33 % of those in the CHOP group. Conclusion GDP regimen is more effective for nonspecific peripheral T-cell lymphoma than the CHOP regimens. Although the hematological toxicity of GDP regimen is serious, the regimen is expected to be the first-line treatment for PTCL. -
Key words:
- Nonspecific peripheral T-cell /
- GDP regimen /
- Efficacy /
- Safety
-
表 1 GDP组与CHOP组病例资料 例
Table 1. Clinical data of the GDP and CHOP patients
表 2 GDP组与CHOP组治疗PTCL临床疗效分析 例（%）
Table 2. Clinical effects of the GDP and the CHOP regimens on the PTCL patients
表 3 GDP组与CHOP组治疗PTCL远期疗效分析 月
Table 3. Long-term efficacy of the GDP and the CHOP treatments for PTCL
表 4 GDP组与CHOP组患者分期与疗效 例（%）
Table 4. Staging and curative effects among the patients in the GDP and the CHOP groups
表 5 GDP组与CHOP组不良反应对比 例（%）
Table 5. Comparison of adverse effects between the GDP and the CHOP groups
-
[1] Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage Ⅰ/Ⅱ nonbulky Hodgkinlymphoma: pretreatment prognostic factors and interim PET[J]. Blood, 2011, 117(20): 5314-5320. doi: 10.1182/blood-2010-10-314260 [2] Piccaluga PP, Agostinelli C, Gazzola A, et al. Prognostic markers in peripheral T-cell lymphoma[J]. Curr Hematol Malig Rep, 2010, 5 (4): 222-228. doi: 10.1007/s11899-010-0062-x [3] Howman RA, Prince HM. New drug therapies in peripheral T-cell lymphoma[J]. Expert Rev Anticancer Ther, 2011, 11(3): 457-472. doi: 10.1586/era.11.4 [4] Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas[J]. J Natl Compr Canc Netw, 2010, 8(3): 288-334. doi: 10.6004/jnccn.2010.0021 [5] Kitagawa J, Hara T, Tsurumi H, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patientswith peripheral T-cell lymphoma, unspecified (PTCL-U)[J]. J Cancer Res Clin Oncol, 2009, 135(1): 53-59. doi: 10.1007/s00432-008-0440-0 [6] Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma [J]. Blood, 2011, 117(25): 6756-6767. doi: 10.1182/blood-2010-05-231548 [7] Yi S, An G, Qi J, et al. The significance of bone marrow involvement in aggressive lymphomas: A retrospectivecomparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B celllymphoma in China[J]. Acta Haematol, 2010, 124(4): 239-244. doi: 10.1159/000321544 [8] Fujiwara SI, Yamashita Y, Nakamura N, et al. High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-celllymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays[J]. Leukemia, 2008, 22(10): 1891-1898. doi: 10.1038/leu.2008.191 [9] 黄慧强, 彭玉龙, 林旭滨, 等. CHOP方案治疗106例外周T细胞淋巴瘤的临床长期随访结果分析[J]. 癌症, 2004, 23(11): 1443-1447. https://www.cnki.com.cn/Article/CJFDTOTAL-AIZH2004S1017.htm [10] Vose JM. The International PTCL Project. International peripheral T-cell lymphoma(PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyelines[J]. Blood, 2005. 106: 811. doi: 10.1182/blood.V106.11.811.811 [11] Escalón MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience[J]. Cancer, 2005, 103(10): 2091-2098. doi: 10.1002/cncr.20999 [12] Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-termoutcome[J]. Ann Oncol, 2010, 21(4): 860-863. doi: 10.1093/annonc/mdp508 [13] Martínez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas[J]. Leukemia, 2005, 19(12): 2254-2263. doi: 10.1038/sj.leu.2403960 [14] 张明智, 邱亚娟, 李文才, 等. 6例皮下脂膜炎样T细胞淋巴瘤临床病理特征及治疗分析[J]. 中国肿瘤临床, 2011, 38(18): 1111-1113. doi: 10.3969/j.issn.1000-8179.2011.18.014 -
点击查看大图
表(5)
计量
- 文章访问数: 29
- HTML全文浏览量: 3
- PDF下载量: 0
- 被引次数: 0
下载:
